Roisin M Dwyer

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5197826/roisin-m-dwyer-publications-by-year.pdf
Version: 2024-04-26

55 papers	2,370 citations	25 h-index	48 g-index
67 ext. papers	2,803 ext. citations	5.5 avg, IF	5.17 L-index

#	Paper	IF	Citations
55	Hydrogels: 3D Drug Delivery Systems for Nanoparticles and Extracellular Vesicles. *Biomedicines*, **2021**, 9,	4.8	3
54	MicroRNAs in Molecular Classification and Pathogenesis of Breast Tumors. *Cancers*, **2021**, 13,	6.6	4
53	Extracellular vesicle release and uptake by the liver under normo- and hyperlipidemia. *Cellular and Molecular Life Sciences*, **2021**, 78, 7589-7604	10.3	4
52	Boron clusters as breast cancer therapeutics. *Journal of Inorganic Biochemistry*, **2021**, 218, 111412	4.2	10
51	Targeting stromal cell Syndecan-2 reduces breast tumour growth, metastasis and limits immune evasion. *International Journal of Cancer*, **2021**, 148, 1245-1259	7.5	5
50	Effect of Breast Cancer and Adjuvant Therapy on Adipose-Derived Stromal Cells: Implications for the Role of ADSCs in Regenerative Strategies for Breast Reconstruction. *Stem Cell Reviews and Reports*, **2021**, 17, 523-538	7.3	1
49	Nanoparticle-Based Delivery of Tumor Suppressor microRNA for Cancer Therapy. *Cells*, **2020**, 9,	7.9	31
48	Investigating the Potential and Pitfalls of EV-Encapsulated MicroRNAs as Circulating Biomarkers of Breast Cancer. *Cells*, **2020**, 9,	7.9	15
47	Extracellular Vesicles for Cancer Therapy: Impact of Host Immune Response. *Cells*, **2020**, 9,	7.9	7
46	Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. *Cancers*, **2020**, 12,	6.6	10
45	Nanoscale structure detection and monitoring of tumour growth with optical coherence tomography. *Nanoscale Advances*, **2020**, 2, 2853-2858	5.1	3
44	Relative and Absolute Expression Analysis of MicroRNAs Associated with Luminal A Breast Cancer- A Comparison. *Pathology and Oncology Research*, **2020**, 26, 833-844	2.6	9
43	Oncological Risk in Autologous Stem Cell Donation for Novel Tissue-Engineering Approaches to Postmastectomy Breast Regeneration. *Breast Cancer: Basic and Clinical Research*, **2019**, 13, 1178223419864896	2.2	1
42	Role of Extracellular Vesicles (EVs) in Cell Stress Response and Resistance to Cancer Therapy. *Cancers*, **2019**, 11,	6.6	53
41	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. *Journal of the National Cancer Institute*, **2019**, 111, 388-398	9.7	45
40	Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379. *Oncogene*, **2018**, 37, 2137-2149	9.2	86
39	Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. *Nature Communications*, **2018**, 9, 3267	17.4	118

38	Dual plasmonic gold nanostars for photoacoustic imaging and photothermal therapy. *Nanomedicine*, **2017**, 12, 457-471	5.6	25
37	Amplification-free detection of microRNAs via a rapid microarray-based sandwich assay. *Analytical and Bioanalytical Chemistry*, **2017**, 409, 3497-3505	4.4	21
36	S100[illegible] as a serum marker in endocrine resistant breast cancer. *BMC Medicine*, **2017**, 15, 79	11.4	14
35	Circulating MicroRNAs in Cancer. *Methods in Molecular Biology*, **2017**, 1509, 123-139	1.4	16
34	Investigation of the effect of dehydration on tissue dielectric properties in ex vivo measurements. *Biomedical Physics and Engineering Express*, **2017**, 3, 045001	1.5	28
33	Engineering Exosomes for Cancer Therapy. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	132
32	Screening of exosomal microRNAs from colorectal cancer cells. *Cancer Biomarkers*, **2016**, 17, 427-435	3.8	24
31	Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer. *International Journal of Cancer*, **2016**, 139, 1443-8	7.5	108
30	MicroRNA-10a is reduced in breast cancer and regulated in part through retinoic acid. *BMC Cancer*, **2015**, 15, 345	4.8	40
29	Solvent-selective routing for centrifugally automated solid-phase purification of RNA. *Microfluidics and Nanofluidics*, **2015**, 18, 859-871	2.8	8
28	Cross Platform Standardisation of an Experimental Pipeline for Use in the Identification of Dysregulated Human Circulating MiRNAs. *PLoS ONE*, **2015**, 10, e0137389	3.7	6
27	Impact of tumour epithelial subtype on circulating microRNAs in breast cancer patients. *PLoS ONE*, **2014**, 9, e90605	3.7	12
26	Impact of mesenchymal stem cell secreted PAI-1 on colon cancer cell migration and proliferation. *Biochemical and Biophysical Research Communications*, **2013**, 435, 574-9	3.4	36
25	Design and performance of a small-animal imaging system using synthetic collimation. *Physics in Medicine and Biology*, **2013**, 58, 3397-412	3.8	14
24	Objective assessment of image quality VI: imaging in radiation therapy. *Physics in Medicine and Biology*, **2013**, 58, 8197-213	3.8	10
23	miR-379 regulates cyclin B1 expression and is decreased in breast cancer. *PLoS ONE*, **2013**, 8, e68753	3.7	63
22	Isolation of secreted microRNAs (miRNAs) from cell-conditioned media. *MicroRNA (Shariqah, United Arab Emirates)*, **2013**, 2, 14-9	2.9	8
21	Influence of stromal-epithelial interactions on breast cancer in vitro and in vivo. *Breast Cancer Research and Treatment*, **2012**, 131, 401-11	4.4	14

20	Relationship between circulating and tissue microRNAs in a murine model of breast cancer. *PLoS ONE*, **2012**, 7, e50459	3.7	40
19	Mesenchymal stem cells in the colorectal tumor microenvironment: recent progress and implications. *International Journal of Cancer*, **2012**, 131, 1-7	7.5	31
18	Relationship between CCL5 and transforming growth factor-β (TGFβ) in breast cancer. *European Journal of Cancer*, **2011**, 47, 1669-75	7.5	21
17	The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. *PLoS ONE*, **2011**, 6, e16023	3.7	23
16	Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer. *Stem Cells*, **2011**, 29, 1149-57	5.8	67
15	Advances in mesenchymal stem cell-mediated gene therapy for cancer. *Stem Cell Research and Therapy*, **2010**, 1, 25	8.3	85
14	Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets?. *Human Gene Therapy*, **2010**, 21, 1506-12	4.8	33
13	Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). *Breast Cancer Research and Treatment*, **2010**, 124, 317-26	4.4	222
12	Dysregulated miR-183 inhibits migration in breast cancer cells. *BMC Cancer*, **2010**, 10, 502	4.8	107
11	Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. *International Journal of Cancer*, **2009**, 124, 326-32	7.5	102
10	Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones. *Breast Cancer Research and Treatment*, **2009**, 115, 279-87	4.4	13
9	Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. *Clinical Cancer Research*, **2007**, 13, 5020-7	12.9	350
8	Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. *Human Gene Therapy*, **2006**, 17, 661-8	4.8	51
7	Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. *Gene Therapy*, **2006**, 13, 60-6	4	57
6	Adenovirus-Mediated and Targeted Expression of the Sodium-Iodide Symporter Permits In Vivo Radioiodide Imaging and Therapy of Pancreatic Tumors. *Human Gene Therapy*, **2006**, 060801084750017	4.8	
5	In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. *Clinical Cancer Research*, **2005**, 11, 1483-9	12.9	74
4	A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. *Molecular Therapy*, **2005**, 12, 835-41	11.7	51
3	The sodium iodide symporter and thyroid disease. *Clinical Endocrinology*, **2002**, 56, 427-9	3.4	8

2	Tissue Iodine Content and Serum-Mediated 125I Uptake-Blocking Activity in Breast Cancer. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 1245-1250	5.6	49
1	Diagnostic and Therapeutic Mesenchymal Stem Cells for Breast Cancer Treatment145-158		